Loading clinical trials...
Loading clinical trials...
A Multi-Center Open-Label Extension Study to Assess the Long-Term Safety Tolerability and Pharmacokinetics of Sofpironium Bromide Gel 15% Applied Topically to Children and Adolescents Age 9-17 Years Previously Enrolled in BBI-4000-CL-105
Conditions
Interventions
Sofpironium Bromide Gel, 15%
Locations
1
United States
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States
Start Date
December 21, 2018
Primary Completion Date
September 6, 2019
Completion Date
September 6, 2019
Last Updated
March 14, 2023
NCT04159610
NCT03658616
NCT02286765
Lead Sponsor
Botanix Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions